Talphera Inc. (TLPH)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $47.07M
Last updated: Nov 17, 2026 at 10:57 AM ET
Talphera Inc. (TLPH) Earnings: Report Dates and Results
Talphera (TLPH) is expected to report earnings on Mar 22, 2027. In the quarter ended Sep 30, 2026, Talphera reported EPS of -$0.05, above the -$0.06 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
TLPH has an expected report date of Mar 22, 2027.
TLPH Earnings Call
The latest TLPH earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, TLPH beat 25, missed 10 and matched 5. The widest gap in the table came in the quarter ended Dec 31, 2022, when EPS landed 900.00% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.05 | -$0.06 | -$0.06 - -$0.05 | +16.67% | Beat | N/A | 2 | 1 up, 0 down | Nov 12, 2026 | N/A |
| Jun 30, 2026 | -$0.06 | -$0.07 | -$0.07 - -$0.06 | +14.29% | Beat | N/A | 2 | 1 up, 0 down | Aug 12, 2026 | N/A |
| Mar 31, 2026 | -$0.05 | -$0.08 | -$0.08 - -$0.08 | +37.50% | Beat | N/A | 1 | 1 up, 0 down | May 13, 2026 | N/A |
| Dec 31, 2025 | -$0.06 | -$0.08 | -$0.08 - -$0.07 | +20.00% | Beat | N/A | 2 | 0 up, 1 down | Mar 23, 2026 | N/A |
| Sep 30, 2025 | -$0.11 | -$0.11 | -$0.14 - -$0.11 | 0.00% | In line | N/A | 2 | 0 up, 1 down | Nov 12, 2025 | $1000 |
| Jun 30, 2025 | -$0.10 | -$0.11 | -$0.13 - -$0.10 | +9.09% | Beat | N/A | 2 | 1 up, 0 down | Aug 14, 2025 | N/A |
| Mar 31, 2025 | -$0.11 | -$0.14 | -$0.17 - -$0.13 | +21.43% | Beat | N/A | 3 | 2 up, 0 down | May 13, 2025 | $27000 |
| Dec 31, 2024 | -$0.07 | -$0.16 | -$0.21 - -$0.12 | +56.25% | Beat | N/A | 3 | 1 up, 0 down | Mar 31, 2025 | $6.68M |
| Sep 30, 2024 | -$0.13 | -$0.20 | -$0.21 - -$0.20 | +35.00% | Beat | N/A | 2 | 0 up, 0 down | Nov 13, 2024 | N/A |
| Jun 30, 2024 | -$0.15 | -$0.20 | N/A | +25.00% | Beat | N/A | N/A | N/A | Aug 14, 2024 | N/A |
| Mar 31, 2024 | -$0.17 | -$0.21 | N/A | +19.05% | Beat | N/A | N/A | N/A | May 14, 2024 | N/A |
| Dec 31, 2023 | -$0.25 | -$0.20 | N/A | -25.00% | Miss | N/A | N/A | N/A | Mar 6, 2024 | $281000 |
| Sep 30, 2023 | -$0.08 | -$0.26 | N/A | +69.23% | Beat | N/A | N/A | N/A | Dec 6, 2023 | $117000 |
| Jun 30, 2023 | -$0.41 | -$0.53 | N/A | +22.64% | Beat | N/A | N/A | N/A | Aug 10, 2023 | $253000 |
| Mar 31, 2023 | -$0.75 | -$0.51 | N/A | -47.06% | Miss | N/A | N/A | N/A | May 10, 2023 | N/A |
| Dec 31, 2022 | -$1.00 | -$0.10 | N/A | -900.00% | Miss | N/A | N/A | N/A | Mar 30, 2023 | $252000 |
| Sep 30, 2022 | -$0.94 | -$1.20 | N/A | +21.67% | Beat | N/A | N/A | N/A | Nov 14, 2022 | N/A |
| Jun 30, 2022 | -$1.15 | -$1.20 | N/A | +4.17% | Beat | N/A | N/A | N/A | Aug 11, 2022 | N/A |
| Mar 31, 2022 | -$1.20 | -$1.20 | N/A | 0.00% | In line | N/A | N/A | N/A | Jun 29, 2022 | N/A |
| Dec 31, 2021 | -$0.06 | -$0.07 | N/A | +7.69% | Beat | N/A | N/A | N/A | Mar 30, 2022 | $2000 |
| Sep 30, 2021 | -$1.40 | -$1.40 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 15, 2021 | $1.86M |
| Jun 30, 2021 | -$1.60 | -$1.60 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 16, 2021 | $443000 |
| Mar 31, 2021 | -$1.60 | -$1.70 | N/A | +5.88% | Beat | N/A | N/A | N/A | Jun 29, 2021 | $511000 |
| Dec 31, 2020 | -$0.10 | -$0.10 | N/A | +3.19% | Beat | N/A | N/A | N/A | Mar 30, 2021 | N/A |
| Sep 30, 2020 | -$2.00 | -$1.80 | N/A | -11.11% | Miss | N/A | N/A | N/A | Nov 5, 2020 | $2.74M |
| Jun 30, 2020 | -$1.60 | -$2.40 | N/A | +33.33% | Beat | N/A | N/A | N/A | Aug 10, 2020 | $2.92M |
| Mar 31, 2020 | -$0.20 | -$0.17 | N/A | -17.65% | Miss | N/A | N/A | N/A | Jun 29, 2020 | $386000 |
| Dec 31, 2019 | -$3.60 | -$3.67 | N/A | +1.91% | Beat | N/A | N/A | N/A | Mar 30, 2020 | $475000 |
| Sep 30, 2019 | -$3.20 | -$4.20 | N/A | +23.81% | Beat | N/A | N/A | N/A | Nov 7, 2019 | $608000 |
| Jun 30, 2019 | -$3.20 | -$4.52 | N/A | +29.20% | Beat | N/A | N/A | N/A | Aug 5, 2019 | $941000 |
| Mar 31, 2019 | -$3.40 | -$4.36 | N/A | +22.02% | Beat | N/A | N/A | N/A | Jun 29, 2019 | $265000 |
| Dec 31, 2018 | -$0.18 | -$0.20 | N/A | +10.00% | Beat | N/A | N/A | N/A | Mar 30, 2019 | $613000 |
| Sep 30, 2018 | -$4.20 | -$4.06 | N/A | -3.45% | Miss | N/A | N/A | N/A | Nov 2, 2018 | $377000 |
| Jun 30, 2018 | -$4.00 | -$3.80 | N/A | -5.26% | Miss | N/A | N/A | N/A | Aug 2, 2018 | $818000 |
| Mar 31, 2018 | -$4.60 | -$5.00 | N/A | +8.00% | Beat | N/A | N/A | N/A | Jun 29, 2018 | $343000 |
| Dec 31, 2017 | -$0.20 | -$0.20 | N/A | 0.00% | In line | N/A | N/A | N/A | Mar 30, 2018 | $740000 |
| Sep 30, 2017 | -$5.60 | -$5.37 | N/A | -4.28% | Miss | N/A | N/A | N/A | Nov 9, 2017 | $1.49M |
| Jun 30, 2017 | -$5.80 | -$5.64 | N/A | -2.84% | Miss | N/A | N/A | N/A | Aug 1, 2017 | $2.66M |
| Mar 31, 2017 | -$6.80 | -$5.44 | N/A | -25.00% | Miss | N/A | N/A | N/A | Jun 29, 2017 | $3.11M |
| Dec 31, 2016 | -$0.21 | -$0.24 | N/A | +12.50% | Beat | N/A | N/A | N/A | Mar 30, 2017 | $6.43M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.38, after -$0.52 the year before. It was -$14.81 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.38 | N/A |
| Dec 31, 2024 | -$0.52 | N/A |
| Dec 31, 2023 | -$1.49 | N/A |
| Dec 31, 2022 | -$4.29 | N/A |
| Dec 31, 2021 | -$4.66 | N/A |
| Dec 31, 2020 | -$3.90 | N/A |
| Dec 31, 2019 | -$13.40 | N/A |
| Dec 31, 2018 | -$12.98 | N/A |
| Dec 31, 2017 | -$18.40 | N/A |
| Dec 31, 2016 | -$14.81 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,000 words across 8 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,046 | 8 | |
| 2026Q2 | Jun 30, 2026 | 4,050 | 8 | |
| 2026Q1 | Mar 31, 2026 | 2,581 | 6 | |
| 2025Q3 | Sep 30, 2025 | 2,568 | 5 | |
| 2025Q2 | Jun 30, 2025 | 4,252 | 7 | |
| 2025Q1 | Mar 31, 2025 | 2,079 | 5 | |
| 2024Q3 | Sep 30, 2024 | 3,589 | 6 | |
| 2024Q2 | Jun 30, 2024 | 3,666 | 7 |
2026Q3 Earnings Call
Opening remarks
Raffi Asadorian CFO Thank you for joining us on the call today. Today we announced our third quarter 2026 financial results and associated business updates in a press release. With me today are Vince Angotti, our Chief Executive Officer, and Dr. Shakil Aslam, Talphera's Chief Medical Officer. Before we begin, I want to remind listeners that during this call, we will likely make forward-looking statements within the meaning of the federal securities laws. These forward-looking statements involve risks and uncertainties regarding the operations and future results of Talphera. Please refer to our press release, in addition to the company's periodic, current, and annual reports filed with the Securities and Exchange Commission, for a discussion of the risks associated with such forward-looking statements. These documents can also be found on our website within the Investors section. I'll now hand the call over to Vince.
Vincent Angotti CEO Thanks, Raffi. Good afternoon, and thank you to everyone joining our call today. I'll begin with an update on our NEPHRO CRRT registrational study evaluating Niyad, our investigational nafamostat-based regional anticoagulant for use in the extracorporeal circuit during continuous renal replacement therapy, or CRRT. This study is being conducted in U.S. hospital ICUs with nephrologists as principal investigators. We recently submitted a briefing document to the FDA requesting a Sprint Meeting to discuss our proposed approach to closing the study by December 31, 2026. I'll explain the rationale for our request and then provide an update on Niyad's commercial opportunity. Over the past several quarters, we've made meaningful progress in advancing the NEPHRO study. Enrollment has now exceeded 75% of our planned target, as we reported last quarter. In recent months, enrollment has been unexpectedly slow due to fewer qualifying patients. Other CRRT studies have recently faced similar enrollment challenges, reflecting the difficulties of conducting clinical trials involving critically ill patients in the intensive care unit. Importantly, as a result of these slower enrollment dynamics in the industry, there is precedent for CRRT studies closing enrollment early and subsequently obtaining regulatory approval. Given these dynamics, we've taken a proactive approach to pursue the most efficient path forward for the NEPHRO study. To that end, we recently submitted a Sprint Meeting request to the FDA, seeking its agreement to conclude enrollment by December 31, 2026, with the number of available patients enrolled at that time. This would be instead of completing the originally planned target of 70 patients, should we not reach that number by the end of the year. Notably, based on our current enrollment, the study is over 80% powered for the primary endpoint. This is a meaningful consideration in evaluating the appropriate sample size for the study.
Frequently Asked Questions About TLPH
When is Talphera's next earnings date?
Talphera's next earnings report is expected for Mar 22, 2027.
Did TLPH beat earnings estimates last quarter?
Yes. Talphera reported EPS of -$0.05 for the quarter ended Sep 30, 2026, above the -$0.06 estimate, a 16.67% surprise.
What EPS do analysts expect from TLPH next quarter?
The consensus EPS estimate for Talphera for the quarter ending Dec 31, 2026 is -$0.07 from 5 analysts, with estimates from -$0.08 to -$0.05.
How often does TLPH beat earnings estimates?
Talphera beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +21.90%.
TLPH pages: Overview, Earnings, Forecast, Financials, Competitors